Gilead Sciences | Ventes



Sales Changement Date
AbbVie USD 15.42B 2.08B 2025-06
Agios Pharmaceuticals USD 12.45M 3.75M 2025-06
ALKERMES USD 390.7M 84.2M 2025-06
Alnylam Pharmaceuticals USD 773.69M 179.5M 2025-06
Amgen USD 9.18B 1.03B 2025-06
Biogen USD 2.6B 170M 2025-06
BioMarin Pharmaceutical USD 825M 80M 2025-06
Bristol-Myers Squibb USD 12.27B 1.07B 2025-06
Eli Lilly USD 15.56B 2.83B 2025-06
Gilead Sciences USD 7.1B 430M 2025-06
GlaxoSmithKline GBP 7.99B 470M 2025-06
Glaxosmithkline GBP 7.99B 131M 2025-06
Incyte USD 1.06B 10M 2025-06
J&J USD 23.74B 1.85B 2025-06
Merck USD 15.81B 280M 2025-06
Moderna USD 142M 34M 2025-06
Neurocrine Biosciences USD 687.5M 114.9M 2025-06
Novartis USD 14.05B 821M 2025-06
Pfizer USD 14.7B 980M 2025-06
PTC Therapeutics USD 178.9M 11.1M 2025-06
Regeneron Pharmaceuticals USD 3.68B 650M 2025-06
Sanofi EUR 9.99B 90M 2025-06
Sarepta Therapeutics USD 611.09M 163.81M 2025-06
United Therapeutics USD 798.6M 4.2M 2025-06
Vertex Pharmaceuticals USD 2.96B 190M 2025-06


Gilead Sciences Ventes - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Sep 2025.